REVO-UWD-19

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameREVO-UWD-19

Drug Alias NameREVO-UWD-19UWD-19

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsImmunologic cytotoxicity

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesWondercel Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWondercel Therapeutics Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A